Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly profit margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 721 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
NeuroSense Therapeutics Ltd.
Market Cap
$7.02M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.80M
Net Profit Margin
-611.47%
TTM Avg
-627.26%
3Y Avg
-917.71%
5Y Avg
-6297.45%
Market Cap
$7.09M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$6.98M
Net Profit Margin
-4791.48%
TTM Avg
-2970.23%
3Y Avg
-7387.99%
5Y Avg
-5910.39%
Market Cap
$7.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-19.45%
5Y Avg
-19.45%
Market Cap
$7.31M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
Market Cap
$7.42M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.33M
Net Profit Margin
-1977.59%
TTM Avg
-1280.67%
3Y Avg
-1780.71%
5Y Avg
-1415.68%
Market Cap
$6.66M
Net Profit Margin
-6523.04%
TTM Avg
-4247.49%
3Y Avg
-2263.82%
5Y Avg
-1493.48%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.02M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.80M | -611.47% | -627.26% | -917.71% | -6297.45% |
| KALA BIO, Inc. (KALA)vs › | $7.09M | 0.00% | 0.00% | -287.91% | -676.70% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -4791.48% | -2970.23% | -7387.99% | -5910.39% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | 0.00% | 0.00% | -19.45% | -19.45% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -0.61% | -82.77% | -131.16% | -372.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Longeveron Inc. (LGVN)vs › | $7.33M | -1977.59% | -1280.67% | -1780.71% | -1415.68% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.66M | -6523.04% | -4247.49% | -2263.82% | -1493.48% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -10978.48% | -12422.83% | -10763.38% | -10131.90% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
